Article
Endotype-phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease.
EBioMedicine - 1 Dec 2019
Hoffmann-Vold Anna-Maria, Weigt S Samuel, Saggar Rajan, Palchevskiy Vyacheslav, Volkmann Elizabeth R, Liang Lloyd L, Ross David, Ardehali Abbas, Lynch Joseph P, Belperio John A
Abstract excerpt
BACKGROUND: Some interstitial lung disease (ILD) patients develop a progressive fibrosing-ILD phenotype (PF-ILD), with similar persistent lung function decline suggesting common molecular pathways involved. Nintedanib, a tyrosine kinase inhibitor targeting the PDGF, FGF, VEGF and M-CSF pathways, has shown comparable efficacy in idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-associated ILD (SSc-ILD)....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.